美国 · SEC FORM 4
Revolution Medicines, Inc.
RVMD · Nasdaq · CIK 0001628171 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
139 同一窗口内观察到的 Form 4 交易行
112 sales · 27 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 8 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-12-05 · Schroeder Thilo.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 11,925,485
- 上期报告
- 9,669,157
- 日均成交量
- 2,564,736
- 回补天数
- 4.7
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-12-05 | Schroeder Thilo | 买入 (P) | Common Stock | 1,304,347 | USD 46.00 | USD 59,999,962 | SEC 申报 ↗ |
| 2023-03-10 | Schroeder Thilo | 买入 (P) | Common Stock | 100,000 | USD 20.46 | USD 2,045,604 | SEC 申报 ↗ |
| 2023-03-07 | Schroeder Thilo | 买入 (P) | Common Stock | 550,000 | USD 22.00 | USD 12,100,000 | SEC 申报 ↗ |
| 2022-07-22 | Schroeder Thilo | 买入 (P) | Common Stock | 250,000 | USD 20.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2022-07-22 | Kim Lorence H. | 买入 (P) | Common Stock | 50,000 | USD 20.00 | USD 1,000,000 | SEC 申报 ↗ |
| 2022-03-28 | Schroeder Thilo | 买入 (P) | Common Stock | 725 | USD 24.71 | USD 17,915 | SEC 申报 ↗ |
| 2022-03-25 | Schroeder Thilo | 买入 (P) | Common Stock | 42,000 | USD 24.79 | USD 1,041,333 | SEC 申报 ↗ |
| 2022-03-24 | Schroeder Thilo | 买入 (P) | Common Stock | 49,119 | USD 24.26 | USD 1,191,627 | SEC 申报 ↗ |
| 2022-03-23 | Schroeder Thilo | 买入 (P) | Common Stock | 53,118 | USD 23.72 | USD 1,259,972 | SEC 申报 ↗ |
| 2022-03-22 | Schroeder Thilo | 买入 (P) | Common Stock | 130,127 | USD 23.35 | USD 3,038,026 | SEC 申报 ↗ |
| 2022-03-21 | Schroeder Thilo | 买入 (P) | Common Stock | 75,731 | USD 20.74 | USD 1,570,334 | SEC 申报 ↗ |
| 2022-03-18 | Schroeder Thilo | 买入 (P) | Common Stock | 82,200 | USD 20.30 | USD 1,668,645 | SEC 申报 ↗ |
| 2022-03-17 | Schroeder Thilo | 买入 (P) | Common Stock | 10,120 | USD 18.78 | USD 190,054 | SEC 申报 ↗ |
| 2022-03-11 | Schroeder Thilo | 买入 (P) | Common Stock | 3,110 | USD 20.93 | USD 65,092 | SEC 申报 ↗ |
| 2022-03-10 | Schroeder Thilo | 买入 (P) | Common Stock | 40,400 | USD 20.61 | USD 832,671 | SEC 申报 ↗ |
Form 4 申报证据
209 transaction lines in the latest 365-day window; 773 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | 卖出 (S) | Common Stock | 6,309 | USD 202.14 | USD 1,275,294 | SEC 申报 ↗ |
| 2026-09-29 | Sandler Alan B. | 期权行权/转换 (M) | Common Stock | 6,000 | USD 58.84 | USD 353,040 | SEC 申报 ↗ |
| 2026-09-25 | Cislini Jeff | 卖出 (S) | Common Stock | 765 | USD 207.32 | USD 158,600 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | 卖出 (S) | Common Stock | 6,309 | USD 202.14 | USD 1,275,294 | SEC 申报 ↗ |
| 2026-09-29 | Sandler Alan B. | 期权行权/转换 (M) | Common Stock | 6,000 | USD 58.84 | USD 353,040 | SEC 申报 ↗ |
| 2026-09-25 | Cislini Jeff | 卖出 (S) | Common Stock | 765 | USD 207.32 | USD 158,600 | SEC 申报 ↗ |
| 2026-09-25 | Mancini Anthony | 卖出 (S) | Common Stock | 3,121 | USD 200.54 | USD 625,885 | SEC 申报 ↗ |
| 2026-09-25 | Mancini Anthony | 期权行权/转换 (M) | Common Stock | 3,121 | USD 33.62 | USD 104,928 | SEC 申报 ↗ |
| 2026-09-24 | Mancini Anthony | 卖出 (S) | Common Stock | 587 | USD 200.00 | USD 117,400 | SEC 申报 ↗ |
| 2026-09-22 | ANDERSON ELIZABETH M | 卖出 (S) | Common Stock | 10,143 | USD 193.04 | USD 1,958,025 | SEC 申报 ↗ |
| 2026-09-22 | ANDERSON ELIZABETH M | 期权行权/转换 (M) | Common Stock | 5,070 | USD 1.12 | USD 5,678 | SEC 申报 ↗ |
| 2026-09-18 | Mancini Anthony | 卖出 (S) | Common Stock | 1,764 | USD 196.94 | USD 347,402 | SEC 申报 ↗ |
| 2026-09-16 | Sandler Alan B. | 卖出 (S) | Common Stock | 341 | USD 199.24 | USD 67,940 | SEC 申报 ↗ |
| 2026-09-16 | Mancini Anthony | 卖出 (S) | Common Stock | 1,774 | USD 199.24 | USD 353,443 | SEC 申报 ↗ |
| 2026-09-16 | Kelsey Stephen Michael | 卖出 (S) | Common Stock | 5,569 | USD 199.23 | USD 1,109,537 | SEC 申报 ↗ |
| 2026-09-16 | Horn Margaret A | 卖出 (S) | Common Stock | 4,967 | USD 199.23 | USD 989,597 | SEC 申报 ↗ |
| 2026-09-16 | GOLDSMITH MARK A | 卖出 (S) | Common Stock | 13,988 | USD 199.23 | USD 2,786,895 | SEC 申报 ↗ |
| 2026-09-16 | Cislini Jeff | 卖出 (S) | Common Stock | 3,366 | USD 199.23 | USD 670,621 | SEC 申报 ↗ |
| 2026-09-16 | Anders Jack | 卖出 (S) | Common Stock | 4,053 | USD 199.24 | USD 807,501 | SEC 申报 ↗ |
| 2026-09-11 | Kelsey Stephen Michael | 卖出 (S) | Common Stock | 92,531 | USD 202.36 | USD 18,724,677 | SEC 申报 ↗ |
| 2026-09-11 | Kelsey Stephen Michael | 期权行权/转换 (M) | Common Stock | 92,531 | USD 41.71 | USD 3,859,488 | SEC 申报 ↗ |
| 2026-09-10 | Mancini Anthony | 卖出 (S) | Common Stock | 15,448 | USD 204.16 | USD 3,153,800 | SEC 申报 ↗ |
| 2026-09-10 | Mancini Anthony | 期权行权/转换 (M) | Common Stock | 9,363 | USD 33.62 | USD 314,784 | SEC 申报 ↗ |
| 2026-09-08 | Kim Lorence H. | 卖出 (S) | Common Stock | 17,090 | USD 209.82 | USD 3,585,811 | SEC 申报 ↗ |
| 2026-08-31 | Kim Lorence H. | 卖出 (S) | Common Stock | 56,000 | USD 203.24 | USD 11,381,290 | SEC 申报 ↗ |
| 2026-08-21 | GOLDSMITH MARK A | 卖出 (S) | Common Stock | 86,000 | USD 209.20 | USD 17,991,043 | SEC 申报 ↗ |
| 2026-08-21 | GOLDSMITH MARK A | 期权行权/转换 (M) | Common Stock | 80,000 | USD 4.73 | USD 378,400 | SEC 申报 ↗ |
| 2026-08-21 | Cislini Jeff | 卖出 (S) | Common Stock | 56,894 | USD 209.24 | USD 11,904,274 | SEC 申报 ↗ |
| 2026-08-21 | Cislini Jeff | 期权行权/转换 (M) | Common Stock | 56,280 | USD 20.00 | USD 1,125,687 | SEC 申报 ↗ |
| 2026-06-29 | Patel Sushil | 卖出 (S) | Common Stock | 5,580 | USD 187.99 | USD 1,048,976 | SEC 申报 ↗ |
| 2026-06-29 | Patel Sushil | 期权行权/转换 (M) | Common Stock | 2,955 | USD 37.54 | USD 110,931 | SEC 申报 ↗ |
| 2026-06-24 | Anders Jack | 卖出 (S) | Common Stock | 20,000 | USD 168.33 | USD 3,366,643 | SEC 申报 ↗ |
| 2026-06-24 | Anders Jack | 期权行权/转换 (M) | Common Stock | 20,000 | USD 18.56 | USD 371,200 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RVMD |
| CIK | 0001628171 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 773 transaction lines from 2020-02-18 to 2026-09-29 39 P purchase lines · 461 S sale lines · 273 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.